Solid Biosciences to Participate in Virtual Fireside Chat at the Chardan 5th Annual Genetic Medicines Manufacturing Summit
April 20 2021 - 7:30AM
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company
focused on advancing meaningful therapies for Duchenne muscular
dystrophy (Duchenne), today announced that Joel Schneider, Ph.D.,
Chief Operating Officer, and Louise Perry, Head of Technical
Operations, will participate in a virtual fireside chat at the
Chardan 5th Annual Genetic Medicines Manufacturing Summit on
Tuesday, April 27, 2021 at 10:30 am ET.
A live webcast of the fireside chat will be
available on the Company’s investor relations website, under the
Events page accessible here:
https://investors.solidbio.com/news-and-events/events. A replay
will be available on the Company's website following the event.
About Solid BiosciencesSolid
Biosciences is a life sciences company focused on advancing
transformative treatments to improve the lives of patients living
with Duchenne. Disease-focused and founded by a family directly
impacted by Duchenne, our mandate is simple yet comprehensive –
work to address the disease at its core by correcting the
underlying mutation that causes Duchenne with our lead gene therapy
candidate, SGT-001. For more information, please visit
www.solidbio.com.
Investor Contact:David CareyFINN
Partners212-867-1768David.Carey@finnpartners.com
Media Contact:Erich SandovalFINN
Partners917-497-2867Erich.Sandoval@finnpartners.com
Solid Biosciences (NASDAQ:SLDB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Solid Biosciences (NASDAQ:SLDB)
Historical Stock Chart
From Apr 2023 to Apr 2024